- Previous Close
25.68 - Open
25.50 - Bid 25.72 x 900
- Ask 25.76 x 1100
- Day's Range
25.39 - 25.81 - 52 Week Range
23.65 - 31.72 - Volume
830,784 - Avg. Volume
813,054 - Market Cap (intraday)
11.231B - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
36.80 - EPS (TTM)
0.70 - Earnings Date Feb 25, 2025
- Forward Dividend & Yield 0.75 (2.91%)
- Ex-Dividend Date Oct 4, 2024
- 1y Target Est
32.55
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
www.smith-nephew.comRecent News: SNN
View MorePerformance Overview: SNN
Trailing total returns as of 12/12/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNN
View MoreValuation Measures
Market Cap
10.96B
Enterprise Value
14.05B
Trailing P/E
36.91
Forward P/E
11.01
PEG Ratio (5yr expected)
0.43
Price/Sales (ttm)
1.99
Price/Book (mrq)
2.16
Enterprise Value/Revenue
2.49
Enterprise Value/EBITDA
14.14
Financial Highlights
Profitability and Income Statement
Profit Margin
5.41%
Return on Assets (ttm)
4.51%
Return on Equity (ttm)
5.84%
Revenue (ttm)
5.64B
Net Income Avi to Common (ttm)
305M
Diluted EPS (ttm)
0.70
Balance Sheet and Cash Flow
Total Cash (mrq)
568M
Total Debt/Equity (mrq)
70.22%
Levered Free Cash Flow (ttm)
247.88M